The EU campaign to vaccinate Europeans against Covid-19 got off to an uneven start in what will be a marathon effort to administer shots to enough of the bloc’s 450 million people to defeat the viral pandemic.
Europe launched a cross-border vaccination program of unprecedented scale on Dec. 27 as part of efforts to end the Covid-19 pandemic that has crippled economies and claimed more than 1.7 million lives around the world.
Countries across the globe shut their borders to Britain on Dec. 21 due to fears about a highly infectious new coronavirus strain, causing travel chaos and raising the prospect of food shortages days before Britain is set to leave the European Union.
Grünenthal agreed to acquire the European rights (excluding Spain and the UK) to AstraZeneca’s Crestor (rosuvastatin) and its associated brands for a total consideration of up to $350 million.
The global tally of confirmed coronavirus cases hit 60 million on Nov. 25, with the pace of new infections accelerating and the United States reporting record numbers of hospitalizations, according to a Reuters tally.
Europe’s new Covid-19 cases doubled in five weeks, propelling the region across the bleak milestone of 10 million total infections, according to a Reuters tally.
(Reuters) – Europe became the second region after Latin America to surpass 250,000 deaths on Saturday, according to a Reuters tally, with record numbers of daily COVID-19 infections reported in the past two weeks.
Global coronavirus cases rose by more than 400,000 for the first time, a record one-day increase as much of Europe enacts new restrictions to curb the outbreak.
In a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines, Covid-19 antibodies last at least three months and so do symptoms for many.
The widely used BCG tuberculosis vaccine will be tested on frontline care workers in Britain for its effectiveness against Covid-19, researchers running the UK arm of a global trial said.